Revance Therapeutics RVNC 深 沪
已收盘 02-06 16:00:00 美东时间
3.65
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 3.65
- 总市值 37.96万
- 52周最高 7.56
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.30
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 42.41
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.30
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
RxSight, Inc. announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy to strengthen its commercial leadership team and accelerate adoption of its Light Adjustable Lens™ (LAL™) technology. Conway brings over 20 years of experience in eye care, pharmaceuticals, and medical aesthetics, while Shields has over 30 years of ophthalmology leadership experience. ...
10-19 13:00
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Outlook Therapeutics appoints Kevin Lundquist as Chief Financial Officer, effective September 1, 2026. Lundquist, with over 20 years of experience in finance and operations across pharmaceutical and medical technology industries, will help build financial and operational infrastructure for the U.S. commercial launch of LYTENAVA™ following its FDA approval. He previously served as CFO at CapsoVision, Inc., leading its IPO, and has extensive experi...
08-27 20:05
药物受理最新动态：Revance Therapeutics, Inc.注射用A型肉毒毒素补充申请获受理
国家药品监督管理局药品审评中心数据显示，2026年7月24日，Revance Therapeutics, Inc.的注射用A型肉毒毒素申请已获受理，受理号为J...
07-24 20:15
RVNC Lawsuit Alert! Class Action Against Revance Therapeutics, Inc.
Aclass actionlawsuit was filed against Revance Therapeutics, Inc. (...
2025-02-21 19:59
Teoxane withdraws takeover offer for Revance Therapeutics
Teoxane withdrew its $3.60 a share offer for Revance Therapeutics after Crown Labs raised its offer to $3.65. Revance ticked lower by 0.3% in premarket trading. Teoxane said that committed financing i...
2025-01-30 22:16
